Fig. 2

Chidamide sensitizes AML cells and stem/progenitor cells to adriamycin. a Kasumi-1 and HL-60/ADM cells were treated with chidamide, adriamycin or both for 24 h. Cell viability was assessed with CCK-8. b Kasumi-1 and HL-60/ADM cells were treated with chidamide (1.00 μmol/L), adriamycin (0.13 μmol/L) or both for 48 h. Apoptosis was determined by flow cytometry. c Patient samples were treated with chidamide (1.00 μmol/L), adriamycin (0.13 μmol/L) or both for 48 h. Apoptosis in CD45 + and CD34 + CD38- cells was measured by flow cytometry. ^*P < 0.05; ^**P < 0.01; Ctrl control, Chi chidamide, ADM Adriamycin, Comb combination